Abstract:Combating influenza is one of the perennial global public health issues to be managed. Antiviral drugs are useful for the treatment of influenza in the absence of an appropriate vaccine. However, the appearance of resistant strains necessitates a constant search for new drugs. In this study, we investigated novel anti-influenza drug candidates using in vitro and in vivo assays. We identified anti-influenza hit compounds using a high-throughput screening method with a green fluorescent protein-tagged recombinant influenza virus. Through subsequent analyses of their cytotoxicity and pharmacokinetic properties, one candidate (IY7640) was selected for further evaluation. In a replication kinetics analysis, IY7640 showed greater inhibitory effects during the early phase of viral infection than the viral neuraminidase inhibitor oseltamivir. In addition, we observed that hemagglutinin (HA)-mediated membrane fusion was inhibited by IY7640 treatment, indicating that the HA stalk region, which is highly conserved across various (sub)types of influenza viruses, may be the molecular target of IY7640. In an escape mutant analysis in cells, amino acid mutations were identified at the HA stalk region of the 2009 pandemic H1N1 (pH1N1) virus. Even though the in vivo efficacy of IY7640 did not reach complete protection in a lethal challenge study in mice, these results suggest that IY7640 has potential to be developed as a new type of anti-influenza drug.IMPORTANCE Anti-influenza drugs with broad-spectrum efficacy against antigenically diverse influenza viruses can be highly useful when no vaccines are available. To develop new anti-influenza drugs, we screened a number of small molecules and identified a strong candidate, IY7640. When added at the time of or after influenza virus infection, IY7640 was observed to successfully inhibit or reduce viral replication in cells. We subsequently discovered that IY7640 targets the stalk region of the influenza HA protein, which exhibits a relatively high degree of amino acid sequence conservation across various (sub)types of influenza viruses. Furthermore, IY7640 was observed to block HA-mediated membrane fusion of H1N1, H3N2, and influenza B viruses in cells. Although it appears less effective against strains other than H1N1 subtype viruses in a challenge study in mice, we suggest that the small molecule IY7640 has potential to be optimized as a new anti-influenza drug.

The Mechanism of Poly-Galloyl-Glucoses Preventing Influenza A Virus Entry into Host Cells

Antiviral Activity and Possible Mechanisms of Action of Pentagalloylglucose (PGG) Against Influenza A Virus

Multivalent Interactions Between Fully Glycosylated Influenza Virus Hemagglutinins Mediated by Glycans at Distinct N-glycosylation Sites

Glycopolymer with Sulfated Fucose and 6'-Sialyllactose as a Dual-Targeted Inhibitor on Resistant Influenza A Virus Strains

Two Escape Mechanisms of Influenza A Virus to A Broadly Neutralizing Stalk-Binding Antibody

Characterization of Potent Fusion Inhibitors of Influenza Virus

Inhibitory Effects and Related Molecular Mechanisms of Huanglian-Ganjiang Combination Against H1N1 Influenza Virus

Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects Against Influenza Virus Infection in Mice and Ferrets

Synthesis and Anti-Influenza Virus Activities of a Novel Class of Gastrodin Derivatives.

A Dna Aptamer Against Influenza A Virus: an Effective Inhibitor to the Hemagglutinin-Glycan Interactions

Design, Synthesis, and Biological Evaluation of Novel Penindolone Derivatives As Potential Inhibitors of Hemagglutinin-Mediated Membrane Fusion.

A small molecule compound targeting hemagglutinin inhibits influenza A virus and exhibits broad-spectrum antiviral activity

Design, synthesis and biological evaluation of novel L-ascorbic acid-conjugated pentacyclic triterpene derivatives as potential influenza virus entry inhibitors.

Identification of a Small-Molecule Inhibitor of Influenza Virus Via Disrupting the Subunits Interaction of the Viral Polymerase.

Chemically Modified Bovine β-Lactoglobulin as a Broad-Spectrum Influenza Virus Entry Inhibitor with the Potential to Combat Influenza Outbreaks

Potent sialic acid inhibitors that target influenza A virus hemagglutinin

Computational Studies On The Substrate Interactions Of Influenza A Virus Pb2 Subunit

Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity

Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses

Porous gold nanoparticles for attenuating infectivity of influenza A virus

Small Molecule Inhibitors of Influenza Virus Entry